Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by SCRI Development Innovations, LLC
Eisai Inc.
Information provided by (Responsible Party):
SCRI Development Innovations, LLC Identifier:
First received: July 20, 2011
Last updated: October 13, 2014
Last verified: October 2014

The investigators propose to evaluate eribulin as adjuvant therapy in patients who do not achieve pCR following standard neoadjuvant chemotherapy. Three cohorts of patients will be evaluated separately: triple-negative, hormone-receptor-positive/HER2-negative, and HER2-positive.

Condition Intervention Phase
Metastatic Breast Cancer
Drug: eribulin mesylate
Drug: Trastuzumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Resource links provided by NLM:

Further study details as provided by SCRI Development Innovations, LLC:

Primary Outcome Measures:
  • Two-Year Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Patients will be treated with eribulin (with or without trastuzumab) and may undergo radiation and hormonal therapy as appropriate, following surgery. The number of patients with no evidence of disease recurrence will be divided by the total number enrolled and treated to give the rate of disease-free survival.

Secondary Outcome Measures:
  • Feasibility, or Whether, Upon Study Completion, the Principal Investigator Feels That Protocol Treatment is A Reasonably Safe and Effective Alternative to Established Standard Treatment for this Disease that is Worthy of Further Investigation [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Feasibility will be defined by the number of patients that are able to complete all protocol-specified therapy without undue toxicity leading to early discontinuation or evidence of disease recurrence necessitating a change in therapy. Final determination of the protocol therapy's feasibility will be made by the study's principal investigator.

  • Assess the toxicity of eribulin in this patient population. [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
    Evaluation of safety among patients in each cohort will also provide sufficient experience to determine the tolerability and toxicity of this regimen. Safety data will be tabulated for patients who receive any amount of trial medication. Adverse events (AEs) will be tabulated by body system, preferred term, severity, and relation to treatment. Worst toxicity grades per patient will be tabulated for selected Adverse events (AE) and laboratory measurements by using NCI CTCAE criteria V4.0.

Estimated Enrollment: 148
Study Start Date: September 2011
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Triple-negative breast cancer
eribulin mesylate
Drug: eribulin mesylate
1.4 mg/m2 IV Days 1 and 8, every 21 days
Other Name: Halaven
Experimental: HER2-positive breast cancer

eribulin mesylate


Drug: eribulin mesylate
1.4 mg/m2 IV Days 1 and 8, every 21 days
Other Name: Halaven
Drug: Trastuzumab
6 mg/kg IV Day 1 every 21 days
Other Name: Herceptin
Experimental: ER/PR Positive/HER2-negative breast cancer
eribulin mesylate
Drug: eribulin mesylate
1.4 mg/m2 IV Days 1 and 8, every 21 days
Other Name: Halaven


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Female patients >=18 years-of-age.
  2. Histologically confirmed breast cancer prior to surgery with the following staging criteria: T1-T3, N0-N2, and M0 (T1N0M0 patients are excluded).
  3. Previous treatment with a minimum of 4 cycles of neoadjuvant anthracycline and/or taxane containing chemotherapy (+trastuzumab in HER2-positive patients).
  4. Patients must be ≥ 21 days and ≤ 84 days from breast surgery and fully recovered. Patients may have had mastectomy or breast conservation surgery with axillary node dissection.
  5. Pathologic CR (pCR) not achieved following neoadjuvant treatment (i.e., residual invasive breast cancer (>5 mm) in the breast or presence of nodal disease at surgery [ypT0, N1-N3a, M0 or ypT1b-T4, N0-N3a, M0].
  6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  7. Recovery from any toxic effects of prior therapy to <=Grade 1 per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.03) except fatigue or alopecia.
  8. Peripheral neuropathy Grade <=2 per NCI CTCAE v4.03 at trial entry.
  9. Normal left ventricular ejection fraction (LVEF), within the institutional limits of normal, as measured by echocardiography (ECHO) or multi-gated (MUGA) scan in patients to receive trastuzumab with eribulin (Cohort C).
  10. Adequate hematologic, hepatic, and renal function
  11. Complete staging work-up to confirm localized disease should include computed tomography (CT) scans of the chest and abdomen/pelvis (abdomen/pelvis preferred; abdomen accepted), a CT scan of the head or MRI of the brain (if symptomatic), and either a positron emission tomography (PET) scan or a bone scan. (Note: a PET/CT is acceptable for baseline imaging in lieu of CT examinations or bone scan). Negative scans performed prior to the initiation of neoadjuvant therapy, or at any subsequent time, are acceptable and do not need to be repeated.
  12. Female patients who are not of child-bearing potential and female patients of child-bearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum pregnancy test performed within 7 days prior to start of trial treatment.
  13. Willingness and ability to comply with trial and follow-up procedures.
  14. Ability to understand the investigative nature of this trial and give written informed consent.
  15. Agree to delay in reconstruction in terms of implants placed in setting of expanders until chemotherapy is completed and the patient has recovered. Expansion of expanders may continue during trial treatment.

Exclusion Criteria:

  1. Presence of other active cancers, or history of treatment for invasive cancer <3 years prior to trial entry (except thyroid, cervical cancer). Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
  2. Radiotherapy prior to the start of study treatment.
  3. History or clinical evidence of central nervous system metastases or other metastatic disease.
  4. Non-healed surgical wound.
  5. Known or suspected allergy/hypersensitivity to eribulin.
  6. Cardiac disease, including: congestive heart failure Class II-IV per New York Heart Association classification;cardiac ventricular arrhythmias requiring anti-arrhythmic therapy; unstable angina (anginal symptoms at rest) or new-onset angina (i.e., began within the last 3 months), or myocardial infarction within the past 6 months.
  7. Chronic use of drugs that cause QTc prolongation.Patients must discontinue use of these drugs 7 days prior to the start of study treatment.
  8. Women who are pregnant or lactating. All females of child-bearing potential must have negative serum or urine pregnancy tests within 48 hours prior to trial treatment.
  9. Patients with known diagnosis of human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.
  10. Prolongation of heart rate-corrected QT interval (QTc) >480 msecs (using Bazett's formula).
  11. Minor surgical procedures (with the exception of the placement of port-a-cath or other central venous access) performed less than 7 days prior to beginning protocol treatment.
  12. History of cerebrovascular accident including transient ischemic attack (TIA), or untreated deep venous thrombosis (DVT)/ pulmonary embolism (PE) within the past 6 months. Note: Patients with recent DVT/PE receiving treatment with a stable dose of therapeutic anti-coagulating agents are eligible.
  13. Patients may not receive any other investigational or anti-cancer treatments while participating in this trial.
  14. History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the trial participation or investigational product(s) administration or may interfere with the interpretation of the results.
  15. Inability or unwillingness to comply with trial and/or follow-up procedures outlined in the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01401959

Contact: Denise A Yardley, M.D. 1-877-691-7274
Contact: Trials Info 1-877-691-7274

United States, Florida
Florida Cancer Specialists North Recruiting
Ft. Myers, Florida, United States, 33916
Florida Cancer Specialists South Recruiting
Ft. Myers, Florida, United States, 33916
Watson Clinic Center for Cancer Care and Research Recruiting
Lakeland, Florida, United States, 33805
Florida Hospital Cancer Insitute Recruiting
Orlando, Florida, United States, 32804
United States, Georgia
Northeast Georgia Medical Center Recruiting
Gainesville, Georgia, United States, 30501
United States, Indiana
Providence Medical Group Recruiting
Terre Haute, Indiana, United States, 47802
United States, Kentucky
Baptist Hospital East Recruiting
Louisville, Kentucky, United States, 40207
United States, Maine
Mercy Hospital Recruiting
Portland, Maine, United States, 04101
United States, Maryland
National Capital Clinical Research Consortium Recruiting
Bethesda, Maryland, United States, 20817
Center for Cancer and Blood Disorders Recruiting
Bethesda, Maryland, United States, 20817
United States, Michigan
Grand Rapids Clinical Oncology Program Recruiting
Grand Rapids, Michigan, United States, 49503
United States, Nebraska
Nebraska Methodist Cancer Center Recruiting
Omaha, Nebraska, United States, 68114
United States, New Jersey
Atlantic Health System Recruiting
Morristown, New Jersey, United States, 07960
Hematology Oncology Associates of Northern NJ Recruiting
Morristown, New Jersey, United States, 07960
United States, Ohio
Oncology Hematology Care, Inc. Recruiting
Cincinnati, Ohio, United States, 45242
United States, South Carolina
South Carolina Oncology Associates Recruiting
Columbia, South Carolina, United States, 29210
United States, Tennessee
Chattanooga Oncology Hematology Associates Recruiting
Chattanooga, Tennessee, United States, 37404
Family Cancer Center Recruiting
Collierville, Tennessee, United States, 38017
Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
Contact: Denise A Yardley, M.D.    877-691-7274   
Principal Investigator: Denise A Yardley, M.D.         
United States, Texas
Texas Health Physician Group Recruiting
Arlington, Texas, United States, 76011
The Center for Cancer and Blood Disorders Recruiting
Fort Worth, Texas, United States, 76104
Sponsors and Collaborators
SCRI Development Innovations, LLC
Eisai Inc.
Study Chair: Denise A Yardley, M.D. SCRI Development Innovations, LLC
  More Information

No publications provided

Responsible Party: SCRI Development Innovations, LLC Identifier: NCT01401959     History of Changes
Other Study ID Numbers: SCRI BRE 186
Study First Received: July 20, 2011
Last Updated: October 13, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by SCRI Development Innovations, LLC:
Metastatic Breast Cancer
Residual Disease

Additional relevant MeSH terms:
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on February 27, 2015